MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
6.85
+0.59
+9.42%
After Hours: 6.72 -0.13 -1.90% 19:13 05/08 EDT
OPEN
6.37
PREV CLOSE
6.26
HIGH
6.86
LOW
6.30
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
8.33
52 WEEK LOW
0.7120
MARKET CAP
517.74M
P/E (TTM)
-10.7671
1D
5D
1M
3M
1Y
5Y
1D
Shattuck Labs Price Target Raised to $11.00/Share From $8.00 by Wedbush
Dow Jones · 1d ago
Shattuck Labs Is Maintained at Outperform by Wedbush
Dow Jones · 1d ago
Shattuck Labs price target raised to $11 from $8 at Wedbush
TipRanks · 1d ago
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $11
Benzinga · 1d ago
SL-325 Data Catalysts and Phase 2 Launch Plans Underpin Buy Rating on Shattuck Labs
TipRanks · 2d ago
Shattuck Labs reports Q1 EPS (13c), consensus (13c)
TipRanks · 2d ago
Shattuck Labs sees cash and cash equivalents sufficient into 2029
TipRanks · 2d ago
Shattuck Labs posts corporate deck outlining DR3 antibody SL-325 for inflammatory diseases
PUBT · 2d ago
More
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.